A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
10 June, 2026
Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day
LATEST NEWS: 10 June 2026 The global radiation therapy
4 June, 2026
Report showcases a year of impactful research, collaboration and consumer engagement
LATEST NEWS: 4 June 2025 TROG’s latest Annual Research